Brain Cancer Clinical Trials

Showing 481-500 of 693 trials

Biomarker Analysis of Central Nervous System Tumors

NCT02692898

Background: The number of people who get tumors of the brain or central nervous system (CNS) is lower than other cancers. But these tumors cause a higher rate of serious effects and even death. Researchers want to test existing samples of tissue from these tumors to learn more about them. This may lead to better treatment. Objective: To study stored samples of CNS tumors to learn more about the tumors and explore new ways to diagnose them. Eligibility: The study will use tissue samples already collected at NIH from people with brain or CNS tumors. Design: The participants will have given their consent in a previous study. Researchers will review the tissue samples and any data collected about them. Researchers will do lab tests and scans on the samples. All data will be kept secure.

Central Nervous System NeoplasmsPrimary Brain NeoplasmsNeoplasms, Brain+2 more

National Cancer Institute (NCI)12 participantsStarted Feb 2016

Bethesda, Maryland, United States

COMPLETEDNA

Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

NCT01108068

This was a pilot study of 10 patients with Osteoporosis-pseudoglioma syndrome (OPPG) from the Old Order Mennonite community and 16 controls, who did not have OPPG. Five of the 10 OPPG patient elected to participate in the Lithium trial and 5 participated only in baseline data (labs, pQCT). The 5 with OPPG who were given lithium for 6 months had both dual energy xray absorptiometry (DXA), peripheral quantitative computerized tomography (pQCT) and lab assessment at baseline and 6 months. Studies in the mouse model of OPPG showed that lithium normalized their bone strength. Controls (n=16) were recruited from the Old Order Mennonite community, to minimize the effects of environmental and lifestyle factors. The controls were not be given lithium. The age range of participants was 4-64 years.

Osteoporosis Pseudoglioma

University of Maryland, Baltimore26 participantsStarted Jul 2010

Lancaster, Pennsylvania, United States

UNKNOWN

Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

NCT04113278

The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression

Brain Tumor Adult

sohaila Essam1 participantsStarted Nov 2019

Biomarker Analysis of Central Nervous System Tumors

Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Related Searches

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Radionecrosis and FDG PET

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy

A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer

Re-craniotomy and Complications After Elective Neurosurgery

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway

NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM

Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors